Menu

Top Stories

Published on Friday, December 2, 2016

RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

The medical journal The Lancet Respiratory Medicine on Thursday, Dec. 1, published findings of the RAPID Open Label Extension study of augmentation therapy for patients with emphysema and Alpha-1 Antitrypsin Deficiency.

N. Gerard McElvaney, MD, lead author

The original RAPID trial, sponsored by CSL Behring, randomly assigned 180 Alphas with emphysema to receive either augmentation therapy or a placebo for two years. RAPID results showed that Alphas who received augmentation therapy had less lung destruction than those on placebo.

In the extension trial, lasting another two years, all subjects received augmentation therapy. The extension trial was offered to all who participated in the original two-year RAPID trial and lived in countries where augmentation therapy was unavailable - 11 countries in all.

"The extension trial is quite remarkable," commented Robert Sandhaus, MD, PhD, who was an investigator in the original RAPID trial but not involved in the extension trial. 

"The extension trial showed that Alphas who received augmentation therapy in the original two years of the RAPID trial continued to show less lung destruction for a full four years while receiving augmentation, and in fact the rate of destruction continued to decline," Sandhaus said. "But the extension trial also showed that no matter when augmentation is started, it will slow lung destruction."

Sandhaus, who is clinical director of the Alpha-1 Foundation and medical director of AlphaNet, said the final message is clear: "The earlier augmentation therapy is begun, the more lung tissue will be saved."

The extension study consisted of two groups: 

Any RAPID study participant who was randomized to receive augmentation therapy for the first two years, wound up receiving a total of four years of augmentation therapy.  Any RAPID participant who had been in the placebo group received augmentation therapy only during the two years of the extension study. All participants received CT scans at intervals throughout the RAPID trial and the extension study in order to assess loss of lung tissue over time.
 
The "Early-Start" group received Alpha-1 augmentation  therapy (Zemaira) during both trials, providing up to four years of continuous treatment, while the "Delayed-Start" group received a placebo during the first two years and then switched to Zemaira in the extension trial, providing up to two years of active treatment. 

Both groups had a similar rate of lung function decline in the last two years when everyone received augmentation therapy. But the "Early-Start" group maintained its advantage, experiencing a lower overall rate of lung density decline. During the extension trial, the "Delayed-Start" group failed to catch-up to their "Early-Start" counterparts.

"RAPID is a landmark study on the disease-modifying effect of A1-PI therapy on the progression of emphysema in patients with severe AATD," said Professor N. Gerard McElvaney, Head of the Department of Medicine Respiratory Research Division, at Beaumont Hospital, Dublin, Royal College of Surgeons in Ireland (RCSI) and lead author of the article.

"With the publication of the RAPID extension study, we have found that the late introduction of A1-PI therapy is still beneficial – but the lung structure lost by the late introduction is never recovered.  RAPID's message is to intervene.  The RAPID extension message is to intervene early," said Kenneth Chapman, MD, director of the Asthma & Airway Centre at the University Health Network in Toronto, Canada.

The full CSL press release

Summary of The Lancet Respiratory Medicine article

 


Print

Papers on Alpha-1 research published in the COPD Foundation Journal

Wednesday, November 7, 2018
The latest issue of the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (Volume 5, Issue 4 – 2018) features papers from presenters at the “3rd Biennial International Research Conference on Alpha-1...
Divider

Mereo BioPharma and TAP work together in clinical study

Tuesday, November 6, 2018
Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program. MPH-966 is an oral neutrophil...
Divider

2018 research grants on Alpha-1 awarded

Tuesday, May 22, 2018
At a cocktail reception the evening of May 21st, held at The Prado at Balboa Park, within the framework of the American Thoracic Society (ATS) 2018 International Conference in San Diego, California, the Alpha-1 Foundation (A1F) announced the...
Divider

Alpha Jonathan Maidment hikes the Pacific Crest Trail

Thursday, May 17, 2018
This story appears in the Spring 2018 issue of Alpha-1-To-One Magazine. Subscriptions are free. Determined and driven are the first two adjectives that come to mind when you get a grasp of the endeavor that 23-year old Jonathan Maidment has...
Divider

First John W. Walsh Translational Research Award granted

Wednesday, January 31, 2018
MIAMI/BOSTON, January 31, 2018 – The Alpha-1 Foundation celebrates the first granting of the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency, an honorable award named after John W. Walsh, co-founder of the...
Divider

Alpha-1 gene therapy trial doses first patient, recruitment continues

Thursday, January 11, 2018
Adverum Biotechnologies, a clinical-stage gene therapy company targeting unmet medical needs in several diseases, is recruiting patients for a clinical trial for Alpha-1 Antitrypsin (A1AT) Deficiency, designed to evaluate the safety and protein...
Divider

Spark Therapeutics explores payment options after revealing price tag for first gene therapy in the US

Thursday, January 4, 2018
Philadelphia based pharmaceutical company, Spark Therapeutics, confirmed conversations with the U.S. Centers of Medicare and Medicaid Services on a proposal that would allow for multi-year payment plans for its innovative treatment, Luxturna, the...
Divider

ATS renames PAR Excellence Award after John W. Walsh

Wednesday, December 13, 2017
The American Thoracic Society (ATS) Public Advisory Roundtable was moved to rename the annual PAR Excellence Award by a unanimous vote in November. The award, presented at the ATS International Conference, will now be referred to as the...
Divider

Alpha-1 research pioneer Jack A. Pierce, MD, passes away

Thursday, December 7, 2017
“One of the early investigators of Alpha–1 and the initial head of the one of the first Pulmonary and Critical Care departments in the country at Washington University in St. Louis has died at the age of 92. I believe few of...
Divider

Recruitment begins for gene therapy clinical trial for Alpha-1 Antitrypsin Deficiency

Tuesday, December 5, 2017
Enrollment for a trial for a new treatment for Alpha–1 related lung disease begins today. Adverum Biotechnologies, in partnership with the Alpha–1 Foundation will be recruiting patients, as well as healthy ZZ and Znull...
Divider

Your helping hand has an impact for Alphas worldwide

Friday, December 1, 2017
When you donate to the Alpha–1 Foundation, you are helping Alphas everywhere by providing support services to newly diagnosed adults and children, giving access to education to both Alphas and medical professionals, allowing for family...
Divider

UK company acquires license for a potential pill-based Alpha–1 lung therapy

Wednesday, November 1, 2017
Mereo BioPharma Group, a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, announced that it has reached an agreement with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.